A MULTICENTER, OPEN LABEL PILOT STUDY OF EARLY (5 DAY) CORTICOSTEROID CESSATION IN DE NOVO RENAL TRANSPLANT RECIPIENTS UNDER SIMULECT, TACROLIMUS, AND SIROLIMUS THERAPY: ONE YEAR RESULTS

2004 ◽  
Vol 78 ◽  
pp. 169 ◽  
Author(s):  
E S Woodle ◽  
F Vincenti ◽  
M Lorber ◽  
A Gritsch ◽  
D Hricik ◽  
...  
Keyword(s):  
Pilot Study ◽  
Renal Transplant ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Open Label ◽  
One Year

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients

2002 ◽  
Vol 74 (7) ◽  
pp. 961-966 ◽  
Author(s):  
Gisela Offner ◽  
Michel Broyer ◽  
Patrick Niaudet ◽  
Chantal Loirat ◽  
Mark Mentser ◽  
...  
Keyword(s):  
Renal Transplant ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Open Label

Once Daily Everolimus Is Safe and Effective in De Novo Renal Transplant Recipients: Six-Month Results of a Pilot Study

2010 ◽  
Vol 42 (4) ◽  
pp. 1308-1311 ◽  
Author(s):  
E. Favi ◽  
G. Spagnoletti ◽  
A. Gargiulo ◽  
M.P. Salerno ◽  
J. Romagnoli ◽  
...  
Keyword(s):  
Pilot Study ◽  
Renal Transplant ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Once Daily

Once-a-Day Administration of Everolimus Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study

2011 ◽  
Vol 43 (4) ◽  
pp. 1010-1012 ◽  
Author(s):  
G. Spagnoletti ◽  
E. Favi ◽  
A. Gargiulo ◽  
M.P. Salerno ◽  
F. Citterio
Keyword(s):  
Pilot Study ◽  
Renal Transplant ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients

Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study

2004 ◽  
Vol 78 (9) ◽  
pp. 1332-1340 ◽  
Author(s):  
Bj??rn Nashan ◽  
John Curtis ◽  
Claudio Ponticelli ◽  
Georges Mourad ◽  
Jonathan Jaffe ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Phase Ii ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Efficacy and Safety of Iguratimod Supplement to the Standard Immunosuppressive Regimen in Highly Mismatched Renal Transplant Recipients: A Pilot Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Jun Tao ◽  
Li Sun ◽  
Zijie Wang ◽  
Hao Chen ◽  
Zhijian Han ◽  
...  
Keyword(s):  
Pilot Study ◽  
Renal Transplant ◽  
De Novo ◽  
Graft Function ◽  
Rejection Rate ◽  
Immunosuppressive Regimen ◽  
Control Group ◽  
Renal Transplant Recipients ◽  
Efficacy And Safety ◽  
Transplant Recipients

Iguratimod (IGU) can mitigate the symptoms of rheumatoid arthritis through its anti-inflammatory effects. The objective of this study was to investigate the clinical efficacy and safety of IGU in highly HLA-mismatched renal transplant recipients, in combination with standard immunosuppressive regimen. This pilot study was designed as an open-label, blank-control, randomized clinical trial on patients recruited from a single transplant center in China. Patients who met the inclusion criteria were randomized to the IGU (n=27) and blank control (n=27) groups. IGU was administrated with the conventional triple immunosuppressive protocol for 52 weeks after kidney transplantation. The incidence of biopsy-proven acute rejection rate was 14.8% (4/27) in the IGU group and 29.6% (8/27) in the control group, P = 0.19. The clinical rejection rate was also substantially reduced in the IGU group (3.7% vs. 18.5%, P = 0.08). De novo donor-specific antibody also showed a decline trend in the IGU group after 52 weeks. The graft function and incidence of adverse events were similar between the two groups. In addition, IGU intervention significantly decreased the number of NK cells throughout the follow-up. In conclusion, our study has shown the possibility that IGU could reduce the allograft rejection rate and de novo DSA with appreciable safety in combination with conventional immunosuppressants. Formal clinical trials were warranted based on current findings.

Sign in / Sign up

Export Citation Format

Share Document